Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog

Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Hachiro Ohnishi, Kazuhiro Toyoda, Hiroaki Taniai, Takeshi Ihara, Hiroaki Ikezaki, Takeo Hayashi, Mosaburo Kainuma, Jun Hayashi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Aim: To evaluate the association between liver stiffness measured by transient elastography (FibroScan) and the efficacy of long-term nucleoside analog (NA) treatment for patients with chronic hepatitis B. Methods: Study 1: Forty-four chronic HBV patients had liver stiffness measured by FibroScan and underwent liver biopsy. Study 2: Group A: 22 patients started NA treatment at entry and FibroScan was done annually for 3years. Group B: 23 patients started NA treatment prior to pretreatment FibroScan measurement, and FibroScan was done for from 3 to 5years after the start of NA treatment. Results: Study 1: The FibroScan values were significantly correlated with fibrosis stage (r=0.672, P<0.0001). Optimal cutoff of FibroScan values were 6.1kPa for≥F1, 6.3kPa for≥F2, 8.9kPa for≥F3 and 12.0kPa for F4. Study 2: For Group A, the baseline median FibroScan value was 8.2kPa. FibroScan values significantly decreased annually for 3years after the start of NA treatment (6.4kPa, 5.8kPa and 5.3kPa at years 1, 2 and 3, respectively). For Group B, the FibroScan values did not significantly improve over the 3years after the start of NA treatment. Conclusions: Liver stiffness, measured by transient elastography, of chronic hepatitis B patients treated with NA showed a rapid decline in the first 3years followed by a more steady transition for from 3 to 5years irrespective of long term virological effect.

Original languageEnglish
Pages (from-to)1178-1188
Number of pages11
JournalHepatology Research
Volume41
Issue number12
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

Elasticity Imaging Techniques
Chronic Hepatitis B
Nucleosides
Liver
Therapeutics
Fibrosis
Biopsy

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. / Ogawa, Eiichi; Furusyo, Norihiro; Masayuki, Murata; Ohnishi, Hachiro; Toyoda, Kazuhiro; Taniai, Hiroaki; Ihara, Takeshi; Ikezaki, Hiroaki; Hayashi, Takeo; Kainuma, Mosaburo; Hayashi, Jun.

In: Hepatology Research, Vol. 41, No. 12, 01.12.2011, p. 1178-1188.

Research output: Contribution to journalArticle

Ogawa, Eiichi ; Furusyo, Norihiro ; Masayuki, Murata ; Ohnishi, Hachiro ; Toyoda, Kazuhiro ; Taniai, Hiroaki ; Ihara, Takeshi ; Ikezaki, Hiroaki ; Hayashi, Takeo ; Kainuma, Mosaburo ; Hayashi, Jun. / Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. In: Hepatology Research. 2011 ; Vol. 41, No. 12. pp. 1178-1188.
@article{56e86a03a856458e88cb88a1113ef99e,
title = "Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog",
abstract = "Aim: To evaluate the association between liver stiffness measured by transient elastography (FibroScan) and the efficacy of long-term nucleoside analog (NA) treatment for patients with chronic hepatitis B. Methods: Study 1: Forty-four chronic HBV patients had liver stiffness measured by FibroScan and underwent liver biopsy. Study 2: Group A: 22 patients started NA treatment at entry and FibroScan was done annually for 3years. Group B: 23 patients started NA treatment prior to pretreatment FibroScan measurement, and FibroScan was done for from 3 to 5years after the start of NA treatment. Results: Study 1: The FibroScan values were significantly correlated with fibrosis stage (r=0.672, P<0.0001). Optimal cutoff of FibroScan values were 6.1kPa for≥F1, 6.3kPa for≥F2, 8.9kPa for≥F3 and 12.0kPa for F4. Study 2: For Group A, the baseline median FibroScan value was 8.2kPa. FibroScan values significantly decreased annually for 3years after the start of NA treatment (6.4kPa, 5.8kPa and 5.3kPa at years 1, 2 and 3, respectively). For Group B, the FibroScan values did not significantly improve over the 3years after the start of NA treatment. Conclusions: Liver stiffness, measured by transient elastography, of chronic hepatitis B patients treated with NA showed a rapid decline in the first 3years followed by a more steady transition for from 3 to 5years irrespective of long term virological effect.",
author = "Eiichi Ogawa and Norihiro Furusyo and Murata Masayuki and Hachiro Ohnishi and Kazuhiro Toyoda and Hiroaki Taniai and Takeshi Ihara and Hiroaki Ikezaki and Takeo Hayashi and Mosaburo Kainuma and Jun Hayashi",
year = "2011",
month = "12",
day = "1",
doi = "10.1111/j.1872-034X.2011.00869.x",
language = "English",
volume = "41",
pages = "1178--1188",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Masayuki, Murata

AU - Ohnishi, Hachiro

AU - Toyoda, Kazuhiro

AU - Taniai, Hiroaki

AU - Ihara, Takeshi

AU - Ikezaki, Hiroaki

AU - Hayashi, Takeo

AU - Kainuma, Mosaburo

AU - Hayashi, Jun

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Aim: To evaluate the association between liver stiffness measured by transient elastography (FibroScan) and the efficacy of long-term nucleoside analog (NA) treatment for patients with chronic hepatitis B. Methods: Study 1: Forty-four chronic HBV patients had liver stiffness measured by FibroScan and underwent liver biopsy. Study 2: Group A: 22 patients started NA treatment at entry and FibroScan was done annually for 3years. Group B: 23 patients started NA treatment prior to pretreatment FibroScan measurement, and FibroScan was done for from 3 to 5years after the start of NA treatment. Results: Study 1: The FibroScan values were significantly correlated with fibrosis stage (r=0.672, P<0.0001). Optimal cutoff of FibroScan values were 6.1kPa for≥F1, 6.3kPa for≥F2, 8.9kPa for≥F3 and 12.0kPa for F4. Study 2: For Group A, the baseline median FibroScan value was 8.2kPa. FibroScan values significantly decreased annually for 3years after the start of NA treatment (6.4kPa, 5.8kPa and 5.3kPa at years 1, 2 and 3, respectively). For Group B, the FibroScan values did not significantly improve over the 3years after the start of NA treatment. Conclusions: Liver stiffness, measured by transient elastography, of chronic hepatitis B patients treated with NA showed a rapid decline in the first 3years followed by a more steady transition for from 3 to 5years irrespective of long term virological effect.

AB - Aim: To evaluate the association between liver stiffness measured by transient elastography (FibroScan) and the efficacy of long-term nucleoside analog (NA) treatment for patients with chronic hepatitis B. Methods: Study 1: Forty-four chronic HBV patients had liver stiffness measured by FibroScan and underwent liver biopsy. Study 2: Group A: 22 patients started NA treatment at entry and FibroScan was done annually for 3years. Group B: 23 patients started NA treatment prior to pretreatment FibroScan measurement, and FibroScan was done for from 3 to 5years after the start of NA treatment. Results: Study 1: The FibroScan values were significantly correlated with fibrosis stage (r=0.672, P<0.0001). Optimal cutoff of FibroScan values were 6.1kPa for≥F1, 6.3kPa for≥F2, 8.9kPa for≥F3 and 12.0kPa for F4. Study 2: For Group A, the baseline median FibroScan value was 8.2kPa. FibroScan values significantly decreased annually for 3years after the start of NA treatment (6.4kPa, 5.8kPa and 5.3kPa at years 1, 2 and 3, respectively). For Group B, the FibroScan values did not significantly improve over the 3years after the start of NA treatment. Conclusions: Liver stiffness, measured by transient elastography, of chronic hepatitis B patients treated with NA showed a rapid decline in the first 3years followed by a more steady transition for from 3 to 5years irrespective of long term virological effect.

UR - http://www.scopus.com/inward/record.url?scp=82255194408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82255194408&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2011.00869.x

DO - 10.1111/j.1872-034X.2011.00869.x

M3 - Article

VL - 41

SP - 1178

EP - 1188

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 12

ER -